Seroprevalence of SARS-CoV-2 in a Cohort of Patients with Multiple Sclerosis under Disease-Modifying Therapies

Autor: Agustín Sancho-Saldaña, Anna Gil Sánchez, Bibiana Quirant-Sánchez, Lara Nogueras, Silvia Peralta, Maria José Solana, Cristina González-Mingot, Yhovanni Gallego, Laura Quibus, Cristina Ramo-Tello, Silvia Presas-Rodríguez, Eva Martínez-Cáceres, Pascual Torres, José Vicente Hervás, Joan Valls, Luis Brieva

Publikováno v: Journal of Clinical Medicine
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
Journal of Clinical Medicine; Volume 11; Issue 9; Pages: 2509

Background: Disease-modifying therapies (DMTs) used to treat multiple sclerosis (MS) alter the immune system and therefore increase the risk of infection. There is growing concern about the impact of COVID-19 on patients with MS (pwMS), especially th

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5fa7a7f2bd3e630853c7f4792348c8a5
https://hdl.handle.net/10459.1/84518